Meeting an important challenge
– –

This is a big challenge with equally big implications. Degenerative brain diseases progress undetected for up to 20 years before detectable clinical symptoms appear. By then, a patient’s viable dopamine receptors in their brain have significantly declined, leading to diseases like Parkinson’s and Lewy Body dementia. As a result, early and accurate detection of the type of tremor is critical to taking advantage of potential therapies.

LikeMinds is taking on this challenge, by developing and commercializing an imaging agent platform capable of supporting early detection of those diseases and dysfunctions related to changes in dopamine receptor function and thereby opening the possibility of aiding in the development of disease modifying therapies in the future

Officers
– –

Peter Savas
Chief Executive Officer


Peter Savas is CEO of LikeMinds, bringing 30 years in executive leadership positions across life sciences. He was CEO of Alseres Pharmaceuticals, Inc., Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease and Restless Legs Syndrome and Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials. Peter also held executive and operating leadership positions with Bristol Meyers, Waters, Millipore, Genex and Zymark.

With a personal mission for entrepreneurism and pursuing advancement in neurologic science, Peter bridges strategic and operational healthcare experience with broad access to industry, academia, regulatory and capital markets leaders. Peter holds a BS in Chemistry from Syracuse University and is credentialed as a Professional Director by the American College of Corporate Directors.

Peter is currently on the board of Aerin Medical and is the Chairman of the National Research Board of the Kennedy Krieger Institute for pediatric neurological disorders. He is also a partner at Targeted Technology Ventures.
Ken Rice, MBA, JD, LLM
Chief Business Officer


Ken Rice is Chief Business Officer of LikeMinds, bringing 25 years of experience in operations, finance, marketing and sales and business development in both private and public life science companies to his position. Ken was for over 10 years executive vice president, CFO and in-house counsel of Alseres Pharmaceuticals, Inc., leading a raise of $72+M in equity and debt capital and partnering the company’s lead diagnostic product in a transaction valued at more than $100M. Prior to joining Alseres, Ken was executive vice president, CFO, Chief Commercial Officer and Counsel at Aderis Pharmaceuticals where he led a value-maximizing strategic M&A transaction culminating in the sale of the company for just under $100M. Ken also held senior executive roles at MacroChem Corporation, Pentose Pharmaceuticals, Inc., Unisyn Technologies, Inc. and Zymark Corporation.

Ken holds an MBA in finance from Babson College, a Juris Doctor (cum laude) from Suffolk University Law School and an LLM in Taxation from Boston University Law School.
Dr. Reinhard Koenig, M.D.
Chief Operating Officer


Dr. Koenig is Chief Operating Officer of LikeMinds, responsible for Product Development and Intellectual Property Development for the current and future LikeMinds product portfolio.

Dr. Koenig has hands-on and executive experience in the bioscience industry (pharma, biotech, medical devices) in product development, regulatory affairs, and commercialization in Europe and the United States. He has been involved in the clinical development of products in neurology, anesthesia, cardiology and regenerative medicine and aesthetic dermatology, leading to successful product registrations in many countries. In clinical development, he has designed and executed small and large clinical trials, domestically and internationally. His experience spans large and smaller companies, among them Piramal Critical Care, Inc., Boehringer Mannheim Therapeutics, Inc., Genentech, Inc., Collagen Aesthetics, Inc., Questcor Pharmaceuticals, Inc., and Glycotex, Inc., ranging from clinical research physician to Chief Executive Officer and Board Member. He has developed several product candidates from early stage to market introduction and has provided product stewardship for marketed products. He has been involved in company start-ups, obtaining investment funds to fuel the growth of companies, obtaining market authorizations for products worldwide and the introduction of products into markets worldwide.

Dr. Koenig received his medical degree (M.D.) from Medical School at Philipps University, Marburg, Germany, and holds a Doctorate in Medicine following a dissertation in environmental toxicology, also from Philipps-University. He has published on various scientific topics and is an inventor and co-inventor of several patents and pending applications. Dr. Koenig also holds an appointment as Adjunct Professor in Temple University’s College of Engineering, Department of Bioengineering.

BOARD MEMBERS
– –

Henry Brem, MD

Professor of Neurosurgery, Ophthalmology, Oncology and Biomedical Engineering
Director, Department of Neurosurgery
Johns Hopkins University School of Medicine

Dr. Brem is the Harvey Cushing Professor of Neurosurgery at The Johns Hopkins University, Director of the Department of Neurosurgery, and Neurosurgeon-in-Chief. He also is a professor of Oncology, Ophthalmology, and Biomedical Engineering.

Over the past 30 years, Dr. Brem has introduced new therapeutic approaches to Neurosurgery. His devotion to patient care, clinical excellence and translational science has brought together a unique group of neurosurgeons and investigators that have changed the field of neurosurgery. Dr. Brem received his undergraduate degree from New York University, his medical degree from Harvard, and trained in neurosurgery at Columbia. At Hopkins, he has built one of the largest brain tumor research and treatment centers in the world. He reinstituted the Hunterian Neurosurgery Laboratory (originally founded by Cushing) and has trained numerous researchers who have revolutionized the fields of intraoperative imaging, angiogenesis, immunotherapy, and controlled release polymers for drug delivery to the brain.

Dr. Brem has changed the surgical treatment of brain tumors by introducing new approaches for targeted therapy. He developed new classes of polymers and microchips for drug delivery that are custom synthesized for the agent being developed. The polyanhydrides, which were the first new treatments for brain tumors that the FDA had approved in 23 years, have been shown in his laboratory to be biocompatible and potent. He then designed and led the clinical trials demonstrating safety and efficacy.

In 1998 Dr. Brem was elected to the Institute of Medicine of the National Academy of Sciences. In 2000 he was awarded the Grass Award by the Society of Neurological Surgeons for meritorious research; in 2001 he received the Founders Award of the Controlled Release Society; in 2004 he received the New York University Distinguished Alumni Award; in 2005 he was co-recipient of the Society for Biomaterials Technology Innovation and Development Award and was named the Coleman Fellow in Life Sciences at Ben-Gurion University. He has been recognized by the Castle Connolly Guide each year from 2002 in “America’s Top Doctors”, and from 2005 – present in “America’s Top Doctors for Cancer”.

In 2010, Dr. Brem’s leadership and his team were recognized by U.S. News & World Report in 2010, when it ranked Johns Hopkins as the #1 neurosurgery program in the nation, a distinction it held for four consecutive years. In 2014 the Neurosurgery Residency Program was ranked in the top three Neurological Surgery Residency Programs in the US by U.S. News & World Report and Doximity.

In 2013, the Society for NeuroOncology and the Section on Tumors of the AANS/CNS named him as the recipient of the Abhijit Guha Award. In 2015 Dr. Brem was selected to receive a Castle Connolly National Physician of the Year Award for Clinical Excellence. The award is given annually to five physicians whose dedication, talents and skills have improved the lives of thousands of people throughout the world.
Gary Frashier, MBA, PE

Former CEO, OSI Pharmaceuticals; Director, Achillion

Mr. Frashier has served as a Chief Executive Officer for over 24 years in life science and specialty chemicals, and has over 17 years of experience in international operations. He served as the CEO and Chairman of OSI Pharmaceuticals, Inc, and it was during his nine year tenure at OSI that the leading genetic-based cancer drug, “Tarceva”, was discovered and developed through proof-of-concept human clinical trials. Tarceva is now sold globally by Roche, Genentech and Astellas for the treatment of many solid tumors with sales of over $1.9 Billion per year. OSI was acquired by Astellas in 2010 for a price of $4 Billion.

Prior to OSI, Mr. Frashier served as Executive Vice President of Millipore Corporation and as President of their International Operations. When Millipore acquired Waters Corporation, he served as President and CEO of their Waters Chromatography subsidiary. Prior to this, he joined Genex Corporation, which discovered, developed and patented the first single-chain antibodies.

Mr. Frashier financed over $250 Million in capital for his companies from a combination of equity fundings and other sources, and is a Strategic Partner in SV Life Sciences, a major Boston venture capital company. He has served as a founder of several life sciences companies, including Merrimack Pharmaceuticals, Eutropics, America Stem Cell, and Apex BioVentures Acquisition Corporation. He has also served on the Board of Directors of Maxim Pharma, Merrimack Pharma, Tekmira, Exegenics, Aderis Pharma, and Alseres Pharma, and is currently on the Boards of Achillion Pharmaceuticals, (NASDAQ:ACHN), ViroXis Corporation, StemBioSys and Metric Medical. Mr. Frashier has a BS in Chemical Engineering from Texas Tech University and an MS from the Massachusetts Institute of Technology in Management (Alfred P. Sloan Fellow).
Robert Langer, ScD

David H. Koch Institute Professor, MIT

Dr. Langer has received over 220 major awards. He is one of 4 living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world’s largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society, the 2013 Wolf Prize in Chemistry, the 2014 Breakthrough Prize in Life Sciences and the 2014 Kyoto Prize. He is also the only engineer to receive the Gairdner Foundation International Award; 82 recipients of this award have subsequently received a Nobel Prize.

In 2015, Dr. Langer received the Queen Elizabeth Prize for Engineering. Among numerous other awards Dr. Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008), the Prince of Asturias Award for Technical and Scientific Research (2008), the Warren Alpert Foundation Prize (2011) and the Terumo International Prize (2012). In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.” In 1989 Dr. Langer was elected to the National Academy of Medicine, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences, and in 2012 he was elected to the National Academy of Inventors.
Paul Sekhri

CEO, Lycera, Versant Ventures, formerly Novartis, Teva

Mr. Sekhri joined Lycera as President and CEO in February 2015. Prior to this he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Lt. Prior to joining Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009 Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development – a department he established to ensure the differential competitive advantage of Novartis’ pipeline.

Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.

Mr. Sekhri has been a Director on sixteen private and public company Boards, and is currently a member of the Board of Directors of Veeva System, Pharming N.V., Enumeral Biomedical, and was a recent board observer at IMS Health.

Additionally, he is on the Board of Directors of the non-profit Cancer Research Institute, the BioExec Institute, Inc., the Industry Advisory Board of the Michael J. Fox Foundation, the TB Alliance, the Tectonic Theatre Project, and was recently elected to the Board of Directors of Young Concert Artists, Inc. Mr. Sekhri also served as a Member of the Board of Trustees of Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council.
Robert Van Nostrand, CPA

Mr. Van Nostrand is a seasoned leader in the biotech and pharmaceutical industries, bringing more than 30 years experience in the private sector to become a valuable industry resource through board participation and industry leadership positions.

For 21 years Mr. Van Nostrand was at OSI Pharmaceuticals, Inc., or OSI, a biotechnology company, serving in a variety of executive positions including Chief Financial Officer as well as SVP and Chief Compliance Officer. After this, Mr. Van Nostrand was EVP and Chief Financial Officer of Aureon Laboratories, Inc., a pathology life science company. Prior to that, Mr. Van Nostrand served as EVP and Chief Financial Officer of AGI Dermatics, a private biotechnology company, from July 2007 to September 2008 when the company was acquired.

Today, Mr. Van Nostrand serves as a director of several biotech and related companies. He is currently on the Board of Directors of Achillion Pharmaceuticals and Enumeral Biomedical Corporation, both biotechnology companies, Intra-Cellular Therapies, a biopharmaceutical company, Yield10 Bioscience, Inc., formerly Metabolix, Inc., a bio agricultural company, and the Biomedical Research Alliance of New York, a private company providing clinical trial services.

Mr. Van Nostrand is also on the Board of the New York Biotechnology Association and was the former chairman, and is on the Foundation Board of Farmingdale University. Mr. Van Nostrand holds a B.S. in Accounting from Long Island University, New York and completed advanced management studies at the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.

ADVISORS
– –

Ann Graybiel, PhD

Dr. Graybiel is an Institute Professor at MIT. Her research is focused on how the regions of the forebrain that influence movement, mood and motivation — the basal ganglia and neural pathways interconnecting the basal ganglia with the cerebral cortex — operate in normal and abnormal conditions. Dr. Graybiel and her group, in order to approach these issues, apply combinations of methods ranging from multi-electrode recordings from neurons in the brain to genetic engineering, optogenetics, fast-scan cyclic voltammetry and designer drug manipulations during behavior.

On the basis of her work, Dr. Graybiel was elected to the National Academy of Sciences of the USA (1988), to the American Academy of Arts and Sciences (1991), and to the Institute of Medicine of the USA (1994). She was awarded the Dow Award in 2002, the Prix Plasticité Neuronale IBSEN in 2005 and the Vanderbilt Prize in 2008. In 2001, Dr. Graybiel was awarded the National Medal of Science of the United States. In 2012 she was awarded the Kavli Prize in Neuroscience.
J. William Langston, MD

Scientific Director, Chief Scientific Officer and Founder, Parkinson’s Institute

Dr. Langston is the Scientific Director, Chief Scientific Officer and Founder of the Parkinson’s Institute in Sunnyvale, California. A graduate of the University of Missouri School Of Medicine, he served as faculty member at Stanford University Medical School and Chairman of Neurology at Santa Clara Valley Medical Center in San Jose, California before founding the Parkinson’s Institute. Dr. Langston gained national and international recognition in 1980s for the discovery of the link between a tainted “synthetic heroin” and parkinsonism. The bad batch of heroin proved to contain a substance known as MPTP, which is selectively toxic to the same nerve cells in the brain that die in Parkinson’s disease. The discovery of the biologic effects of this compound led to a renaissance of the basic and clinical research in Parkinson’s disease.

He authored or co-authored 360 publications in the field of neurology, most of which are on Parkinson’s disease and related disorders. Dr. Langston’s current research interests include the study of mechanisms of neuronal degeneration, the etiology definition of Parkinson’s disease, the development of new strategies to slow or halt disease progression, and ways to identify the disease in its earliest “pre-motor” stages. He has received numerous awards, including the Distinguished Achievement Award from Modern Medicine, the Sarah M. Poiley Award from the New York Academy of Sciences, the James Parkinson 30th Anniversary Award from the Parkinson’s Disease Foundation, the Distinguished Clinical Investigator Award from Roche Pharmaceuticals, the Movement Disorders Research Award from the American Academy of Neurology and the Robert A. Pritzker Prize for Leadership in Parkinson’s Research. He is the founding member of the Scientific Advisory Board for the Michael J Fox Foundation for Parkinson’s Research, which he continues to serve on.

Dr. Langston’s work has been featured in both print and broadcast media including major network newscasts, the BBC Evening News, Prime Time Live, 20/20, Good Morning America, the Today Show, and the McNeil-Lehrer Report. His work has been profiled in both Time and Newsweek and has been the subject of two NOVA programs on PBS: “The Case of the Frozen Addicts” and “Brain Transplants”. He published a book, which is also titled “The Case of the Frozen Addicts” as well as editing numerous scientific texts. Most recently he and his work were profiled on the 2009 PBS Frontline “Special Report on Parkinson’s: My Father, My Brother, and Me”.
Jerome Lisk, MD

Dr. Lisk earned his medical degree at the Medical College of Virginia and completed his Internship at UCLA then his Neurology Residency & Movement Disorders fellowship at the University of Texas at Houston. He has been an advisor for biotech startups and done research on Immunotoxin therapy at the University of Michigan.

Memberships include The American Academy of Neurology, The Movement Disorder Society, American Association for Physician Leadership and Association of American Physicians & Surgeons.

Dr. Lisk has been on the Medical Advisory Committee for the California State Athletic Commission, Board of Directors of the American Heart Association, African-American Task Force for the Western States, Alzheimer’s Association Board. Member Southwest Missouri Chapter, expert reviewer for the California Medical Board and a member of the Bylaws Committee for the California Neurology Society.

Dr. Lisk is a 2013 Graduate of the American Academy of Neurology Palatucci Advocacy Leadership Forum and 2016 Graduate of the American Academy of Neurology Diversity Leadership Program. 2010 NAACP Man of Valor Award Recipient. He has also been voted as one of Pasadena Top Docs by Pasadena Magazine from 2011 to 2015.

Dr. Lisk is currently a member of the Christus Health IRB Committee, member of the American Academy of Neurology Diversity Subcommittee, Trinity Leadership Curriculum and Virtual Visit Committee at Christus Trinity Mother Frances Hospital.
Saira Ramasastry, MS

Ms. Ramasastry, Managing Partner of Life Sciences Advisory, is a seasoned industry insider with over 20 years of transaction and advisory experience. Prior to LSA, she helped found and establish the leading life sciences franchise on Wall Street at Merrill Lynch and was responsible for emerging biotech coverage.

Ms. Ramasastry is a recognized thought leader on life sciences public-private alliances and is frequently called upon as a speaker. She serves on the Industry Advisory Board of the Michael J Fox Foundation for Parkinson's Research, lead business advisor for the European Prevention of Alzheimer's Dementia (EPAD) consortium and as a Special Advisor for the G8 Dementia Initiatives. She serves on the Boards of Directors of Sangamo Biosciences (NASDAQ: SGMO), Repros Therapeutics (NASDAQ: RPRX) and Pain Therapeutics (NASDAQ: PTIE).

Ms. Ramasastry has a B.A. in Economics with Honors and Distinction from Stanford University where she graduated Phi Beta Kappa, and advanced degrees in Management Science & Engineering and Management Studies from Stanford University and the University of Cambridge. She is a lecturer for the Bioscience Enterprise Program and serves on the Advisory Council of the Cambridge Judge Business School. She was named one of Silicon Valley’s 40 Under 40 and recently named a top life sciences advisor by Acquisition International and CorporateLiveWire.
John P. Seibyl, MD

Dr. Seibyl is Managing Director and Distinguished Scientist at inviCRO, LLC having merged in 2016 with Molecular Neuroimaging, a company he co-founded in New Haven, Connecticut. He is also Senior Scientist at the Institute for Neurodegenerative Disorders and Associate Clinical Professor of Diagnostic Radiology, Yale University. Prior to this, Dr. Seibyl was Chief of the Section of Nuclear Medicine and the Director of the Yale PET Center and NeuroSPECT Center within the Yale School of Medicine. He is board-certified in both Psychiatry and Nuclear Medicine, having completed training in both specialties at Yale. Dr. Seibyl has won numerous grants and contracts over the course of his 25 year career in brain imaging. He is currently the PI for the Imaging core of the Parkinson’s Progression Marker Initiative (PPMI) Trial, a large, multicenter, International trial of Parkinson’s disease progression.

Active in his community, Dr. Seibyl is a past president of the Greater New York Chapter of the SNMMI and the Brain Imaging Council. He was awarded the 2015 Kuhl-Lassen award by SNMMI for his research contributions including development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. He served on the editorial board of the European Journal of Nuclear Medicine, is a frequent reviewer and author for top-tier nuclear imaging journals, and serves on international panels for his work in neurodegenerative disease imaging. Dr. Seibyl is an author on over two hundred publications on brain imaging.
Robert Sgroi

Head of Marketing, North America and International, Piramal Imaging

Mr. Sgroi has over 20 years of diversified experience in the field of Molecular Imaging. As a Board Certified and Registered Nuclear Medicine Technologist, he has combined his clinical experience and business acumen to support his passion to build a career centered around making a positive impact on the lives of patients, their families and those who care for them.

Prior to joining Piramal Imaging, Mr. Sgroi spent nearly 20 years at GE Healthcare. His leadership roles at GE included Global Brand Director for a $350 million division of GE Healthcare and Brand Leader for DaTscan (Ioflupane I-123). DaTscan was the first significant molecular imaging agent to come to the US market in over a decade and the world’s first Schedule II radiopharmaceutical. As Brand Leader, he had sole responsibility for all aspects of the commercialization of this product including its 2009 U.S. launch.

Mr. Sgroi started his career with GE Healthcare as Senior Nuclear Medicine Technologist in the New York radiopharmacy. He was crossed trained in health physics and became the site Radiation Safety Officer. He also held positions in Clinical Research, Business Analytics and Brand Management. Mr. Sgroi holds a dual degree in both Business management and Nuclear Medicine.
Thomas H. Tulip, PhD

President & Chief Executive Officer, FPMI

Dr. Tulip has spent more than 30 years in the development and commercialization of radiopharmaceuticals and imaging agents, with a track record of success in R&D, business development, brand and alliance management, and international business.

Prior to joining FluoroPharma Medical Inc. in 2015, he served in corporate leadership roles from 2011-2015 at Navidea BioPharmaceuticals, Inc., where he led one of the few successful recent launches of an innovative radiopharmaceutical; established global partnerships; and in-licensed a pair of best-in-class neuroimaging assets. Previously, Dr. Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS), and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. While at BMS and DuPont, he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise; successfully built the BMS Medical Imaging international business; and led planning activities for innovative PET tracers at LMI/BMS. He was a Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies.

Dr. Tulip was Chairperson of the Society of Nuclear Medicine Corporate Advisory Board and served as a Director of the Council on Radionuclides and Radiopharmaceuticals. He serves on the Board of Directors and Executive Committee of the Medical Imaging Technology Association (MITA) and has lead its PET Working Group. He earned a B.S. from the University of Vermont, and an M.S. and Ph.D. from the Northwestern University.

© 2017 LikeMinds | All Rights Reserved.